DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: HCD122

First Posted Date: 2005-10-04

Last Posted Date: 2018-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT00231166

Locations: 🇺🇸
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer, New York, New York, United States
🇺🇸
University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102, Philadelphia, Pennsylvania, United States
🇺🇸
Fred Hutchinson Cancer Research Center Dept. of FHCRC, Seattle, Washington, United States

and more 3 locations

Long-term Study of Ciclosporin for Atopic Dermatitis

Phase 3

Completed

Conditions: Severe Atopic Dermatitis

First Posted Date: 2005-10-04

Last Posted Date: 2011-11-02

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00232063

Verification Study of Ciclosporin for Atopic Dermatitis

Phase 3

Completed

Conditions: Severe Atopic Dermatitis

First Posted Date: 2005-10-04

Last Posted Date: 2011-11-02

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00232076

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: EC-MPS, Tacrolimus

First Posted Date: 2005-09-29

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 291

Registration Number: NCT00229138

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

Phase 3

Completed

Conditions: Acromegaly

Interventions: Drug: Octreotide LAR

First Posted Date: 2005-09-26

Last Posted Date: 2012-04-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT00225979

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Brain Metastasis
Non-small Cell Lung Cancer

Interventions: Drug: Patupilone

First Posted Date: 2005-09-22

Last Posted Date: 2021-02-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT00219297

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of California Davis Cancer Center UC Davis Cancer (3), Sacramento, California, United States

and more 9 locations

Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Zoledronic acid

First Posted Date: 2005-09-22

Last Posted Date: 2017-05-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00219271

Locations: 🇬🇷
Novartis Investigative Site, Athens, Greece

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease With End of Dose Wearing Off

Interventions: Drug: Carbidopa/levodopa/entacapone

First Posted Date: 2005-09-22

Last Posted Date: 2017-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 359

Registration Number: NCT00219284

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension
Left Ventricular Hypertrophy
Overweight

Interventions: Drug: Aliskiren 150/300 mg
Drug: Losartan 50/100 mg
Drug: Aliskiren placebo
Drug: Losartan 50/100 mg placebo

First Posted Date: 2005-09-22

Last Posted Date: 2011-05-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 460

Registration Number: NCT00219141

Locations: 🇦🇷
sites in Argentina, Argentina, Argentina
🇩🇪
sites in Germany, Germany, Germany
🇪🇸
sites in Spain, Spain, Spain

and more 6 locations

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Philadelphia Positive Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: STI571 400 mg
Drug: STI571 600 mg

First Posted Date: 2005-09-15

Last Posted Date: 2021-07-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 293

Registration Number: NCT00171249

Locations: 🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy